Table 1. Patient characteristics.
| TNM 1 short term survivors trainingset Group A (n=10) | TNM 1 long term survivors trainingset Group B (n=10) | TNM 1validatingset Group C (n=17) | TNM 1short follow upsetGroup D (n=12) | TNM 2 short term survivors training set Group E (n=5) | TNM 2 long term survivors training set Group F (n=5) | TNM 2validatingset Group G (n=7) | TNM 2 short follow upset Group H (n=5) | |
|---|---|---|---|---|---|---|---|---|
| Gender | ||||||||
| Male n(%) | 6 (60) | 5 (50) | 8 (47) | 1 (8) | 2 (40) | 2 (40) | 4 (57) | 2 (40) |
| Female n(%) | 4 (40) | 5 (50) | 9 (53) | 11 (92) | 3 (60) | 3 (60) | 3 (43) | 3 (60) |
| Age | ||||||||
| Median years at surgery (range) | 65.5 (46-74) | 64 (54-75) | 64 (28-80) | 64.5 (41-84) | 67 (52-70) | 80 (48-88) | 65 (56-76) | 61 (49-68) |
| Median months survival (range) | 34.6 (10.4-52.9) | 73.9 (62.9-99.3) | 59.6 (11.7-99.2) | 24.3 (0.7-42.2) | 12.2 (8.1-23.3) | 36.9 (30.6-73.5) | 29.6 (23.3-98.2) | 19.1 (1.3-23.5) |
| TNM | ||||||||
| Stage 1A n(%) | 4 (40) | 5 (50) | 5 (29) | 3 (25) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Stage 1B n(%) | 6 (60) | 5 (50) | 12 (71) | 9 (75) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Stage 2A n(%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (40) | 2 (40) | 1 (16) | 3 (60) |
| Stage 2B n(%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (60) | 3 (60) | 6 (84) | 2 (40) |
| N0 n(%) | 10 (100) | 10 (100) | 17 (100) | 12 (100) | 2 (40) | 3 (60) | 4 (57) | 2 (40) |
| N1 n(%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (60) | 2 (40) | 3 (43) | 3 (60) |
| Tobacco pack-years | ||||||||
| None n(%) | 0 (0) | 0 (0) | 3 (17.6) | 1 (8.3) | 4 (80) | 1 (20) | 1 (15) | 2 (40) |
| <30 n(%) | 1 (10) | 2 (20) | 5 (29.5) | 3 (25) | 0 (0) | 2 (40) | 4 (55) | 1 (20) |
| 31-49 n(%) | 3 (30) | 5 (50) | 3 (17.6) | 0 (0) | 0 (0) | 2 (40) | 1 (15) | 1 (20) |
| >50 n(%) | 6 (60) | 3 (30) | 6 (35.3) | 8 (66.6) | 1 (20) | 0 (0) | 1 (15) | 1 (20) |
| EGFR status | ||||||||
| Mutated EGFR mutated/tested (% mutated) | 0/5 (0) | 0/2 (0) | 2/8 (25) | 0/10 (0) | 1/4 (25) | 0/2 (0) | 0/3 (0) | 0/3 (0) |
| Amplified EGFR amplified/tested (% amplified) | 1/5(20) | 0/2 (0) | 2/8 (25) | 3/9 (33) | 3/4 (75) | 1/2 (50) | 0/2 (0) | 1/3 (30) |
| Mutated or amplified EGFR positive/tested (% positive) | 1/5 (20) | 0/2 (0) | 3/8 (37.5) | 3/9 (33) | 3/4 (75) | 1/2 (50) | 0/3 (0) | 1/3 (30) |
| Disease status | ||||||||
| Locally recurrent (yes/no/unknown) | (8/1/1) | (0/10/0) | (7/10/0) | (0/12/0) | (4/1/0) | (2/3/0) | (0/7/0) | (0/5/0) |
| Metastatic (yes/no/unknown) | (8/1/1) | (0/10/0) | (4/11/2) | (0/12/0) | (5/0/0) | (2/3/0) | (1/6/0) | (0/5/0) |
| Adjuvant therapy n(%) | 0 (0) | 0 (0) | 2 (12) | 2 (17) | 2 (40) | 1 (20) | 4 (57) | 3 (60) |
| Cause of death | ||||||||
| Alive n(%) | 0 (0) | 10 (100) | 11 (65) | 12 (100) | 0 (0) | 5 (100)) | 6 (85) | 5 (100) |
| Deceased of Lung cancer n(%) | 10 (100) | 0 (0) | 6 (35) | 0 (0) | 5 (100) | 0 (0) | 1 (15) | 0 (0) |